INTRODUCTION

Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide, with enormous economic and social consequences [1]. TBI results from direct damage to the brain caused by an external, physical force, which can lead to a state of decreased consciousness, physical functioning, or deterioration of cognitive ability [2]. Many secondary lesions in patients with TBI occur in a medium-long term period, and the appearance of brain and pulmonary complications is highly prevalent. Direct brain injury and altered levels of consciousness decrease the protection of the airways and alter the natural defense barrier, which adds to reduced mobility and multiple pathophysiological deficits inherent to the injury [3].

The brain–lung interaction can seriously affect patients with traumatic brain injury, triggering a vicious cycle that worsens patient prognosis. Although the mechanisms of the interaction are not fully elucidated, several hypotheses, notably the "blast injury" theory or "double hit" model, have been proposed and constitute the basis of its development and progression. The brain and lungs strongly interact via complex pathways from the brain to the lungs but also from the lungs to the brain. The main pulmonary disorders that occur after brain injuries are neurogenic pulmonary edema, acute respiratory distress syndrome, and ventilator-associated pneumonia, and the principal brain disorders after lung injuries include brain hypoxia and intracranial hypertension. All of these conditions are key considerations for management therapies after traumatic brain injury and need exceptional case-by-case monitoring to avoid neurological or pulmonary complications. This review aims to describe the history, pathophysiology, risk factors, characteristics, and complications of brain–lung and lung–brain interactions and the impact of different old and recent modalities of treatment in the context of traumatic brain injury.

Key Words: lung injury; neurocritical care; neurogenic pulmonary edema; traumatic brain injuries; ventilator-induced lung injury
and triggers several lung injuries, like neurogenic pulmonary edema (NPE), acute respiratory distress syndrome (ARDS), and ventilation-associated pneumonia (VAP). In the same way, lung injuries can affect the brain due to alterations in pulmonary physiology having repercussions at the systemic level, leading to neurological disorders which can be triggered mainly by hypoxia and intracranial hypertension [3,4]. The brain and lungs share fundamental connections that are compromised in patients with TBI. This injury becomes a vicious cycle that worsens patient condition (Figure 1). Considering the increasing global incidence of TBI, deficient access to healthcare in many parts of the world, and inadequate methods of treatment [1], we present a narrative review of the available evidence on the mechanisms of brain-lung interaction in patients with trauma as well as new therapeutic implications and possible management strategies that could reduce brain and pulmonary complications and improve the prognosis of patients in order to provide a basis for future research.

HISTORY

Extracranial complications frequently occur in patients with TBI; among them, pulmonary disorders are common and deteriorate patient condition, leading to serious neurological outcomes. Brown-Séquard [5] was the first to describe the interaction between TBI and the lungs in 1871 in his experimental traumatic injury to the pons of guinea pigs that resulted in pulmonary hemorrhage and edema. In 1969, Simmons et al. [6] evaluated an autopsy series of patients who died from TBI that reported the vast majority of those who died within few minutes after trauma to have pulmonary edema, which allowed them to affirm that TBI is decisive in the development of pulmonary edema with consequent respiratory dysfunction. In 1976, Theodore and Robin introduced the “explosion theory” to explain NPE in patients with TBI [7] that declared an excess of catecholamines and consequent positive regulation of sympathetic signal transduction to be responsible for the increase in pulmonary venous pressure and transudative edema. Finally, although NPE was estimated to have an incidence of only 1% after cerebral trauma in 1997, a mortality of 60%–100% was demonstrated regardless of its etiology, which triggered the alarms to consider it a life-threatening condition after it was demonstrated to increase of intracranial pressure (ICP), where pulmonary hemorrhage and edema.

**KEY MESSAGES**

- The brain-lung interaction is key in the pathophysiology of complications in traumatic brain injury.
- Neurogenic pulmonary edema, acute respiratory distress, and ventilator-associated pneumonia are the main conditions passed from the brain to the lungs.
- Cerebral hypoxia and intracranial hypertension are the main pulmonary-to-brain conditions.

---

Figure 1. Vicious circle of the interaction between acute lung injury in patients with traumatic brain injury: a double impact model.
immediate therapeutic interventions are essential [8].

Likewise, in terms of frequent pulmonary complications, ARDS is also notable. Its concept has evolved from the old name idiopathic pulmonary anasarca, postulated by Laënnec in 1821, until its recent definition in Berlin [9]. In 1967, Ashbaugh et al. [10] presented the concept of ARDS as respiratory distress syndrome, which was improved in 1988 by Murray et al. [11] by including the description of a multi-section system. Later, the European-American Consensus Conference conceptualized the criteria for acute lung injury (ALI). However, it was decided not to use the ALI term and to stratify ARDS into three levels of severity in the more recent Berlin definition [9].

In 1997, Bratton and Davis [12] evaluated the incidence of ALI in comatose patients after isolated TBI and found that it was 20%, showing a three-fold greater probability of dying or surviving in a vegetative state. In a study published in 2003, it was reported that 31% of patients with severe TBI developed ALI, with a greater number of days in mechanical ventilation (MV), a worse neurological outcome, and mortality of 38% [13]. The presence of ALI or ARDS complicates the treatment of patients with TBI because hypoxia causes additional damage to the brain and because therapies used to protect the lungs and improve patient oxygenation can reduce cerebral blood flow and increase ICP [14]. In a 20-year retrospective cohort study of patients with TBI, an increase in the prevalence of ALI or ARDS was found, and a greater association with comorbidities, such as congestive heart failure, hypertension, chronic obstructive pulmonary disease, chronic kidney disease, and liver failure, as well as increased risk of sepsis, multi-organ dysfunction, and in-hospital mortality was found [15].

There is a high frequency of infection in patients with TBI due to a predisposition attributed to compromised host defenses after brain trauma and the need for MV in these patients [16]. In 1992, Piek et al. [17] evaluated the determinants of recovery after severe brain trauma and found that pneumonia was the second most frequent complication (40.6%) on the fifth to tenth days after the trauma; furthermore, they emphasized the fact that many of them were not preventable in critically ill patients and could only be managed through quick diagnosis, prompt etiology identification, and opportune treatment [17]. Later, pneumonia was found in 60% of 125 patients with closed head trauma. Of which, 47.8% corresponded to early pneumonia and were associated with lower scores on the Glasgow coma scale (GCS), longer intubation time, intensive care duration, and hospitalization [18].

VAP is among the most important subtypes of nosocomial infections, and the incidence of this type of pneumonia in patients with brain injury ranges from 28% to 40% [19]. In 1999, Ranieri et al. [20] demonstrated for the first time that MV induced a cytokine response in the lungs and plasma, which was associated with higher rates of multi-organ failure. However, they suggested that attenuation of this inflammatory response could be a useful strategy to minimize overstrecthing and cell recruitment in lungs, with possible improvements in clinical outcomes. In 2004, Bronchard et al. [21] published a prospective observational study of patients with TBI who required tracheal intubation for neurological reasons and ventilation for at least 2 days and reported a 41.3% incidence of early-onset pneumonia with low arterial oxygen pressure (PaO\textsubscript{2}), decreased inspired fraction of oxygen (FiO\textsubscript{2}), fever, hypotension, and intracranial hypertension. They concluded that early-onset pneumonia led to secondary lesions and neurological deterioration.

**BRAIN–LUNG INTERACTIONS IN BRAIN TRAUMA**

**From Brain to Lung Physiopathology**

Shortly after presenting brain damage of any kind, preclinical lung injury appears even without obvious symptoms—the effect manifests with alterations in the mechanics of the respiratory system and hypoxemia [22]. Although the mechanisms by which brain damage leads to alterations in lung function are not clear, the development of NPE, inflammatory processes, neurotransmitter-related compromise, and even adverse effects secondary to the administration of neuroprotective therapies can be considered fundamental [23]. A well-recognized theory to explain the pathophysiology responsible for lung damage is “blast injury,” which suggests that a sympathetic storm after a sudden increase in ICP induces a massive release of catecholamines. This results in a transient increase in intravascular pressure, rupture of the alveolar-capillary membrane, and consequent development of NPE [22].

As well as NPE constituting a fundamental part of the genesis of pulmonary dysfunction after TBI, the systemic inflammatory response also plays an important role in its development [24]. The intracranial inflammatory response occurs after brain injury, and pro-inflammatory cytokines, such as interleukins (IL-1, IL-6, IL-8) and tumor necrosis factor, are produced locally in the injured brain tissue. First, microglia and astrocytes are the main sources of inflammatory mediators. Then, the
alteration of blood-brain barrier permeability allows its discharge into systemic circulation. Likewise, all this production of inflammatory mediators (“first hit”) concomitant to the procedures used in the treatment of patients with TBI; such as MV; surgical procedures; or complications, namely infections (“second hit”), make up the recently described “double hit” model (Figure 1) [4].

Neurogenic pulmonary edema

NPE is a clinical condition that manifests as acute respiratory distress, occurring secondary to insult to the central nervous system (CNS). By definition, this condition is characterized by a large accumulation of extravascular pulmonary fluid, which appears suddenly and immediately after serious lesions of the CNS, mostly the brainstem [25]. If the clinical presentation is evident, the diagnosis should be assumed when acute pulmonary edema is observed in association with CNS injury in the absence of primary pulmonary or cardiovascular injury. However, this idea is imprecise because the literature does not present a complete understanding of the exact pathogenesis [26-28].

Nowadays, it is known that alteration of the CNS causes a sympathetic overflow, leading to a state of systemic vasconstriction. This leads to the accumulation of blood from systemic circulation into the pulmonary circulation, resulting in pulmonary hypertension and an increase in pulmonary capillary hydrostatic pressure [29]. The change in pressures is responsible for the leakage of intravascular fluid to both the alveoli and the pulmonary interstitial space through two mechanisms: first, Starling forces, and second, changes in permeability in the capillary walls [25].

Elevated systemic arterial pressure and increased left atrial and pulmonary hydrostatic pressure, culminating in pulmonary edema, are attributed to peaks in sympathetic activity, particularly α-adrenergic, induced by lesions of the hypothalamus or spinal cord [30]. This sympathetic hyperactivity is triggered by a sudden increase in ICP or a decrease in cerebral blood flow [31].

Acute respiratory distress

In patients with brain lesions, a high incidence rate of ARDS has been described [4]. This affects the morbidity and mortality of patients with brain lesions in all cases, increasing inpatient mortality until three times when it appears after TBI. Risk factors for the development of ARDS have been identified. First, the severity of the initial brain injury characterized by a low GCS and abnormalities in initial brain computed tomography (CT) (displacement midline and global CT findings) and second, induced hypertension, administration of vasoactive drugs, and a history of drug abuse have been reported to be independent factors of ARDS in severe TBI. Similarly, there are general risk factors, such as male sex; young age; ethnicity; and a history of chronic arterial hypertension, diabetes, chronic obstructive pulmonary disease, development of sepsis, cardiovascular, renal, and hematological dysfunctions [15,32]. On the other hand, it has been determined over the years that the distribution of ARDS has a bimodal character, consisting of an early peak on the second or third day after the start of MV and a later peak on the eighth or ninth day after the start of ventilation, often related to pneumonia [4].

Ventilation-associated pneumonia

VAP is defined as an infection of the lung parenchyma that occurs in patients exposed to invasive MV for at least 48 hours. Currently, this pathology remains one of the most frequent infections in those patients who require invasive MV, and despite recent advances in microbiological tools and epidemiology, the diagnostic criteria remain controversial [33]. MV is an effective life-saving intervention method for critically ill patients. Thus, it is widely used in intensive care units (ICUs). This strategy allows the supply of oxygen and the elimination of carbon dioxide (CO₂) with strict control of PaO₂ and PaCO₂. The main objective of MV is the prevention of secondary cerebral ischemia and incrementally positive neurological outcomes. However, prolonged MV can increase the risk of infection and a variety of complications [4].

Ventilation time and ICU stay have been reported to be significantly longer in patients with VAP than in those without VAP. An Egyptian study found that the incidence of VAP increased from 5% in patients who received 1 day of MV to 65% in patients who received 30 days of MV [34]. An artificial airway must be established to perform MV, which changes the defense function of the resident airway mucosa and decreases the ability to swallow and the ability of cilia to clear. Subsequently, bacteria can enter the lower respiratory tract directly or cross the space between the wall of the tracheal tube and the airways to begin the infectious process [35].

VAP has been frequently identified in neurological patients due to decreased level of consciousness, micro aspirations, and even massive aspiration. The main risk factors for developing VAP in patients with brain injury are polytransfusion, age, obesity, diabetes, immunosuppression status, chronic
lung disease, and the use of barbiturates. In addition, sedation, 
the use of muscle relaxants, prior antibiotic treatment, and the 
absence of an inclined position during MV increase the risk 
of developing VAP [4]. A study conducted in Serbia in 2015 
showed that the incidence of VAP in patients with severe TBI 
was up to 49.7%, much higher than the mean incidence of VAP 
without TBI [36].

The microorganisms that cause VAP vary with respect to the 
duration of MV; the length of stay in the ICU; the previous, pro-
longed or irresponsible use of antimicrobials; the local micro-
bial prevalence; and the appearance of any potential epidemic 
phenomenon in a given ICU. The most common gram-nega-
tive bacteria involved in VAP are Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella pneumoniae, and Acinetobacter 
species, while Staphylococcus aureus is the main gram-positive 
microorganism, being the most common pathogen reported in 
VAP in patients with severe TBI [37,38].

In general, it is recognized that a normal oropharyngeal 
flora is generally involved in VAP that occurs in the first 4 days 
of hospitalization in previously healthy patients who have not 
received or receive antibiotics regularly or inadequately. On 
the other hand, in patients who present the clinical characteris-
tics of VAP after at least 5 days of hospitalization and who 
present its risk factors, it is more likely that their infection is 
due to multidrug-resistant (MDR) pathogens. However, MDR 
pathogens can be isolated in early-onset VAP, primarily in the 
presence of certain risk factors, such as antimicrobial exposure 
within the previous 90 days [39,40].

From the Lung to the Brain 
Physiopathology

Due to a large number of communication pathways between 
the peripheral nervous system and the CNS [9], lung injuries 
or pathologies that affect proper oxygenation can lead to al-
terations at the neuronal level, like memory problems, disori-
entation, cognition, and language alterations, through various 
routes [41]. Among these pathways, we find three to be funda-
mental: humoral, neural, and cellular. The first pathway con-
ists of the recruitment of monocytes or macrophages in the 
lungs, which increases the levels of inflammatory mediators 
that can directly reach the CNS through the humoral route. 
The neuronal pathway refers to the fact that there is a connec-
tion between the brain and the nucleus of the solitary tract 
through the afferents of the vagal pathway. Finally, the cellular 
pathway is directly regulated by the release of tumor necrosis 
factor in the lungs that stimulates the release of monocyte 
chemoattractant protein-1 at the brain level, which increases 
the recruitment of activated monocytes both at the level of the 
CNS and the periphery nervous system [9].

Cerebral hypoxia

Hypoxemia is a potential risk factor for the development of 
long-term cognitive impairment. Lower PaO₂ values were 
associated with cognitive impairment in general and execu-
tive dysfunction specifically. Long-term neuropsychological 
damage is common in survivors of ALI [42]. Despite the mech-
anism of connection or integration that causes neurological 
alterations not being widely understood, several experimental 
studies have tried to explain the mechanism by which lung 
damage can lead to neurological disorders and uncover the 
role of hypoxemia in these changes. In a 2005 experimental 
study with 14 pigs, Fries et al. [43] induced hypoxemia in two 
groups by repeated lung lavages (lung injury group) or by 
reducing the inspired oxygen fraction (hypoxia-only group), 
concluding that the same degree of hypoxemia induced in the 
lavage model of ALI results in greater brain damage, assessed 
by S-100 protein and histopathologic findings when compared 
to the group in which hypoxemia was induced at the same 
degree by reducing the inspired oxygen fraction. This suggests 
that ALI leads to neuropathological changes independent of 
hypoxemia [43].

Bickenbach et al. [44] also examined the influence of ALI 
and hypoxia on neurological outcomes in pigs. In their study, 
they demonstrated that neurocognitive compromise after ALI 
seems due to a more pronounced inflammatory response and 
complex MV. However, these changes only resulted in mild 
changes in histopathology in terms of perivascular inflamma-
tion in the hippocampal CA1 sector, and the caudate nucleus 
and the putamen were not significantly different between the 
groups [44].

Mechanisms for the deterioration of neurologic function 
after lung injury remain unclear and may include hypoxia and 
the effects of MV and its consequential inflammatory response 
[44]. A systematic review in 2021 showed an association be-
tween MV and acute cognitive impairment, and preclinical 
papers showed acute cognitive impairment after MV, describ-
ing greater neuroinflammation and lower cognitive scores in 
subjects with a longer MV duration [45]. On the other hand, 
patients with ARDS may experience long periods of hypoxia, 
leading to the hypothesis that they might develop brain lesions 
and atrophy similar to those observed in other disorders with 
concomitant hypoxia [46]. Kamuf et al. [47] carried out the first
study focusing on the neuroinflammatory injury potential of early ARDS, and they found hints indicating an increased cerebral expression of inflammatory cytokines within 6 hours after the onset of lung injury but no signs of histopathologic injury [47]. The mechanism of changes in the brain-lung relationship that occur in hypoxic situations could be explained by specific signaling pathways. Some of these pathways have been established in animal models, such as in naked mole-rat hypoxia models, in which hypoxia altered the Akt/mammalian target of rapamycin pathway, which correlated with a general decrease in the ribosomal protein biosynthesis machinery activity in the lungs and brain [48].

Intracranial hypertension

In brain-injured patients, especially those in critical care, there is a serious detriment to respiratory function with the elevation of PaCO₂. This directly causes the vasodilation of cerebral arteries and a consequent increase in cerebral blood volume, which might result in a higher ICP if intracranial compliance is reduced [22]. Moreover, PaO₂ and PaCO₂ can also change with MV and positive end-expiratory pressure (PEEP), which raise ICP by increasing pleural pressure and diminishing venous return. [49]. Intracranial hypertension and ARDS were thought to be independent pathological entities, but recent results have shown that they both interact and actually trigger each other. A study in mechanically ventilated pigs found that ARDS induces a systemic inflammatory response with aberrantly elevated cytokines and neutrophil counts, which has a detrimental effect on the brain and acts synergistically with intracranial hypertension [50].

Therapeutic Implications: the Conflict between the Brain and Lungs

The management of patients with TBI represents a great challenge and includes multiple strategies that seek to preserve the brain-lung balance. The objective of ventilatory support is to maintain adequate oxygenation (PaO₂ ≥60 mm Hg) and avoid hypercapnia [51] in addition to protecting ICP and thus preventing secondary brain injury [22,52]. For this reason, the traditional ventilatory strategy for the prevention and treatment of intracranial hypertension was to impart high tidal volume to maintain mild hypocapnia (PaCO₂ 30 to 35 mm Hg) [51]. However, it has been shown that high tidal volume can affect the brain, inducing intracranial hypertension and causing a deleterious event (second hit) in the lung, which is a particularly sensitive organ [22].

A neurological study of ICU patients established that high tidal volume ventilation was an independent predictor of ARDS in patients with severe brain injury [53]. Likewise, a study in rats found that low tidal volume minimized lung morphological and functional changes, improving oxygenation and reducing lung damage compared to the use of high tidal volumes [54]. Thus, research suggests that maintaining a low tidal volume could be more beneficial in patients with or without ARDS since it reduces the risk of pulmonary complications after TBI [55].

According to the guidelines of the “Brain Trauma Foundation,” prolonged prophylactic hyperventilation with PaCO₂ ≤25 mm Hg is not recommended for the reduction of elevated ICP, and it should be avoided, especially during the first 24 hours after the injury when the cerebral blood flow often declines critically. In addition, it is mentioned that hyperventilation with measurements of jugular oxygen saturation or partial pressure of oxygen of brain tissue to monitor oxygen supply is only temporarily recommended [56]. These recommendations are based on the fact that hyperventilation can be harmful since severe hypocapnia and subsequent cerebral vasoconstriction can lead to hypoxia in brain tissue and compromised blood flow velocities and compliance. Finally, when ARDS and TBI coexist, it is necessary to find a balance between CO₂ control and lung protection, although there are no absolute contraindications for the use of protective ventilation in the treatment of TBI without significant intracranial hypertension. Thus, PaCO₂ values should be established on a case-by-case basis in accordance with ICP [51,52].

On the other hand, PEEP increases pleural and intrathoracic pressure and, consequently, can alter central venous return and cause an increase in ICP; therefore, the management of null or low PEEP (≤5 cm H₂O) has been recommended in mechanically ventilated brain-injured patients [57]. However, the transmission of PEEP into the thoracic cavity depends on the properties of the lungs and chest wall. An experimental study conducted by Chapin et al. [58] showed that when the lung elastance is high, PEEP can minimize airway pressure transmission, whereas high elastance in the chest wall can significantly increase pleural pressure and eventually ICP. Both ideas were supported by several studies. First, a prospective study of 21 comatose patients with severe head injury or subarachnoid hemorrhage who required MV and PEEP demonstrated that PEEP exerts no significant effects on cerebral hemodynamics in patients with high respiratory system elastance [49]. Likewise, in a prospective pilot study that evaluated 20 patients
with TBI and ARDS, it was reported that an increase in PEEP up to 15 cm H₂O resulted in an increase in oxygen pressure and saturation in brain tissue without an increase in ICP or a decrease in cerebral perfusion pressure (CPP) [59]. Similarly, a study found that the effect of PEEP on ICP was more profound in patients with higher elastance chest walls [60]. Nevertheless, PEEP can alter CPP in hypovolemic conditions [57], which seems to indicate that an increase in PEEP can be safely applied to impart beneficial brain effects in brain-injured ARDS patients as long as they are normovolemic with high lung elastance and low chest wall elastance.

Recruitment maneuvers (RMs) have been reported as useful strategies capable of improving oxygenation, restoring alveolar recruitment, and optimizing ventilation-perfusion mismatch [52]. However, for the same reasons as PEEP, RMs could lower blood pressure and increase ICP by interfering with the return of venous blood, causing an elevation in intrathoracic pressure. Thus, the use of RMs can be safe only with strict monitoring of systemic and cerebral parameters and the use of progressive maneuvers [4].

Likewise, the prone position has been shown to increase oxygenation through different mechanisms, such as net recruitment, increased homogeneous distribution of alveolar ventilation, and protection from ventilation-associated lung injury [4]. The clinical case of a patient with thoracic and brain trauma who subsequently developed ARDS showed an improvement in lung function indices with moderate and very transient effects of ICP that resolved shortly after the change in position (supine position) [61]. Nevertheless, this maneuver has been poorly studied in patients with brain injuries, so prone positioning may be considered in patients with concurrent severe ARDS (PaO₂/FiO₂ ratio <150) and TBI but do not have significant ICP elevation [62].

It has recently been shown that inflammasomes NLRP 1,2,3 (NOD-like receptors purine domain-containing) NLRC 4 (NOD-like receptor CARD domain-containing), and AIM 2 (absent in melanoma 2) play a role in TBI, facilitating the rapid activation of the innate immune response [63], which leads to exaggerated systemic inflammation and contributes to the damage of other organs, favoring the pathogenesis of ALI/ARDS after TBI [64]. Therefore, these inflammasome proteins can serve as possible biomarkers to assess the severity of injury and as possible therapeutic targets for inhibition [63].

Currently, there are no effective therapies to mitigate disability. However, new studies are paving the way for future interventions. In a study by Lee et al. [65], they found evidence that inhibiting neuronal death and preventing the activation of the inflammasome provides beneficial effects by reducing the potentially harmful consequences of activated microglia and leukocyte infiltration after penetrating TBI. Also, inflammasome inhibition through the use of neutralizing antibodies against inflammasome proteins has been tested and has had some success in preclinical models of TBI [63].

In a study evaluating the effects of enoxaparin after TBI, a significant decrease in the ALI score as well as neutrophil and macrophage infiltration into the lungs 24 hours after injury was found. This study demonstrated that enoxaparin attenuates ALI and inhibits the expression of the inflammasome in the brain and lungs after TBI, supporting the hypothesis that the inhibition of the neural-respiratory inflammasome axis that is activated after TBI may have therapeutic potential [66].

Regarding NPE patients, few studies have reported on specific treatments in humans, and only a few studies in animals have focused on treatment with α-blockers to limit massive sympathetic discharge after brain injuries [4]. This emphasizes the need for more studies with directed strategies to reduce the organic consequences and improve patient prognosis.

**CONCLUSION**

The brain-lung relationship arises from the interaction of several factors which are triggered by trauma responses and can communicate between the organs through different pathways. Nevertheless, almost always after a TBI, only the brain effect at the pulmonary level is considered, with very little consideration of the detrimental reverse consequences. Acute lung damage caused by ARDS or MV can worsen neurological functions in patients with TBI by humoral, neuronal, and cellular communications and by the interaction of numerous elements released locally or systemically in trauma response. Hence, therapeutic strategies should be able to minimize the impact of TBI in critical patients, both at the pulmonary and neurological levels.

MV can have a beneficial effect on oxygenation and cerebral perfusion in patients with TBI. However, the estimation of tidal volume, PEEP, and RMs is also necessary in addition to considering systemic and cerebral parameters, such as ICP, PaCO₂, PaO₂, and properties of the lungs and chest wall due to the close relationship that they have to the elevation of ICP. Finally, we conclude that the management of patients with TBI should be established on a case-by-case basis considering individual characteristics to avoid the appearance of neurological and
pulmonary complications that influence prognosis or constitute long-term sequelae with greater morbidity and mortality, additional costs to health services, and the inevitable decrease in patient quality of life. Although new strategies targeting the inflammatory cascade are being investigated, experimental and clinical studies are needed to evaluate the brain and lung level effects.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Ariana Alejandra Chacón-Aponte
https://orcid.org/0000-0003-2005-5781

Érika Andrea Durán-Vargas
https://orcid.org/0000-0003-0896-0869

Jaime Adolfo Arévalo-Carrillo
https://orcid.org/0000-0002-8599-3616

Iván David Lozada-Martínez
https://orcid.org/0000-0002-1960-7334

Maria Paz Bolaño-Romero
https://orcid.org/0000-0001-8962-6947

Luis Rafael Moscote-Salazar
https://orcid.org/0000-0002-4180-6962

Pedro Grille
https://orcid.org/0000-0002-2099-4378

Tariq Janjua
https://orcid.org/0000-0001-5852-0090

AUTHOR CONTRIBUTIONS

Conceptualization: all authors. Data curation: AACA, EADV, JAAC, IDLM, MPBR. Formal analysis: AACA, EADV, JAAC, IDLM, MPBR. Methodology: all authors. Project administration: IDLM, LRMS, PG, TJ. Writing–original draft: all authors. Writing–review & editing: all authors.

REFERENCES

1. Johnson WD, Griswold DP. Traumatic brain injury: a global challenge. Lancet Neurol 2017;16:949-50.
2. Okidi R, Ogwang DM, Okello TR, Ezati D, Kyegombe W, Nyeko D, et al. Factors affecting mortality after traumatic brain injury in a resource-poor setting. BJNS Open 2020;4:320-5.
3. Lee K, Rincon F. Pulmonary complications in patients with severe brain injury. Crit Care Res Pract 2012;2012:207247.
4. Mrozek S, Constantin JM, Geeraerts T. Brain-lung crosstalk: implications for neurocritical care patients. World J Crit Care Med 2015;4:163-78.
5. Brown-Séquard CE. On the production of hemorrhage, anemia, edema and emphysema in the lungs by injuries to the base of the brain. Lancet 1871;97:6.
6. Simmons RL, Martin AM Jr, Heisterkamp CA 3rd, Ducker TB. Respiratory insufficiency in combat casualties. II. Pulmonary edema following head injury. Ann Surg 1969;170:39-44.
7. Theodore J, Robin ED. Speculations on neurogenic pulmonary edema (NPE). Am Rev Respir Dis 1976;113:405-11.
8. Brambrink AM, Dick WF. Neurogenic pulmonary edema: pathogenesis, clinical picture and therapy. Anaesthesist 1997;46:953-63.
9. López-Aguilar J, Fernández-Gonzalo MS, Turon M, Quílez ME, Gómez-Simón V, Jódar MM, et al. Lung-brain interaction in the mechanically ventilated patient. Med Intensiva 2013;37:485-92.
10. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319-23.
11. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
12. Bratton SL, Davis RL. Acute lung injury in isolated traumatic brain injury. Neurosurgery 1997;40:707-12.
13. Holland MC, Mackersie RC, Morabito D, Campbell AR, Kivett VA, Patel R, et al. The development of acute lung injury is associated with worse neurologic outcome in patients with severe traumatic brain injury. J Trauma 2003;55:106-11.
14. Contant CF, Valadka AB, Gopinath SP, Hanay HH, Robertson CS. Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury. J Neurosurg 2001;95:560-8.
15. Rincon F, Ghosh S, Dey S, Maltenfort M, Vibbert M, Urtecho J, et al. Impact of acute lung injury and acute respiratory distress syndrome after traumatic brain injury in the United States. Neurosurgery 2012;71:795-803.
16. Dziedzic T, Slowik A, Szczudlik A. Nosocomial infections and immunity: lesson from brain-injured patients. Crit Care 2004;8:266-70.
17. Pick J, Chesnut RM, Marshall LF, van Berkum-Clark M, Klauber MR, Blunt BA, et al. Extracranial complications of severe head injury. J Neurosurg 1992;77:901-7.
18. Worotyla SP, Morgan AS, Mackay L, Bernstein B, Barba C. Factors associated with early onset pneumonia in the severely brain-injured patient. Conn Med 1995;59:643-7.
19. Fàbregas N, Torres A. Pulmonary infection in the brain injured patient. Minerva Anestesi 2002;68:285-90.
20. Ranieri VM, Suter PM, Tortorella C, De Trollio R, Dayer JM, Brienza A, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999;282:54-61.
21. Bronchard R, Albaladejo P, Brezac G, Geoffroy A, Seince PF, Morris W, et al. Early onset pneumonia: risk factors and consequences in head trauma patients. Anesthesiology 2004;100:234-9.
22. Koutsoukou A, Katsiari M, Orfanos SE, Kotanidou A, Daganou M, Kyriakopoulou M, et al. Respiratory mechanics in brain injury: a review. World J Crit Care Med 2016;5:65-73.
23. Gonzalvo R, Martí-Sistac O, Blanch L, López-Aguilar J. Bench-to-bedside review: brain-lung interaction in the critically ill. A pending issue revisited. Crit Care 2007;11:216.
24. Mascia L. Acute lung injury in patients with severe brain injury: a double hit model. Neurocrit Care 2009;11:417-26.
25. Al-Dhahir MA, Das JM, Sharma S. Neurogenic pulmonary edema [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Sep 31]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532984/.
26. Kennedy JD, Hardin KA, Parikh P, Li CS, Seyal M. Pulmonary edema following generalized tonic clonic seizures is directly associated with seizure duration. Seizure 2015;27:19-24.
27. Raja HM, Herwadkar AV, Paroutoglou K, Lilleker JB. Neurogenic pulmonary oedema complicating a lateral medullary infarct. BMJ Case Rep 2018;2018:bcr2018225437.
28. Romero Osorio OM, Abaunza Camacho JE, Sandoval Briceño D, Lasalvia P, Narino Gonzalez D. Postictal neurogenic pulmonary edema: case report and brief literature review. Epilepsy Behav Case Rep 2017;9:49-50.
29. Šedý J, Kuneš J, Zicha J. Pathogenetic mechanisms of neurogenic pulmonary edema. J Neurotrauma 2015;32:1135-45.
30. Busl KM, Bleck TP. Neurogenic pulmonary edema. Crit Care Med 2015;43:1710-5.
31. Zhang L, Yao J, Zhang T, Jin J, Zeng X, Yue Z. Stellate ganglion block may prevent the development of neurogenic pulmonary edema and improve the outcome. Med Hypotheses 2013;80:158-61.
32. Rincon F, Maltenfort M, Dey S, Ghosh S, Vibbert M, Urtecho J, et al. The prevalence and impact of mortality of the acute respiratory distress syndrome on admissions of patients with ischemic stroke in the United States. J Intensive Care Med 2014;29:357-64.
33. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med 2020;46:888-906.
34. Othman AA, Abdelazim MS. Ventilator-associated pneumonia in adult intensive care unit prevalence and complications. Egypt J Crit Care Med 2017;5:61-3.
35. Ding C, Zhang Y, Yang Z, Wang J, Jin A, Wang W, et al. Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis. BMC Infect Dis 2017;17:468.
36. Jovanovic B, Milan Z, Markovic-Denic L, Djuric O, Radinovic K, Doklestin K, et al. Risk factors for ventilator-associated pneumonia in patients with severe traumatic brain injury in a Serbian trauma centre. Int J Infect Dis 2015;38:46-51.
37. Di Pasquale M, Ferrer M, Esperatti M, Crisafulli E, Giunta V, Li Bassi G, et al. Assessment of severity of ICU-acquired pneumonia and association with etiology. Crit Care Med 2014;42:303-12.
38. Huang Y, Jiao Y, Zhang J, Xu J, Cheng Q, Li Y, et al. Microbial etiology and prognostic factors of ventilator-associated pneumonia: a multicenter retrospective study in Shanghai. Clin Infect Dis 2018;67(Suppl 2):S146-52.
39. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-111.
40. Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013;39:672-81.
41. Bickenbach J, Zoremba N, Fries M, Dembinski R, Doering R, Ogawa E, et al. Low tidal volume ventilation in a porcine model of acute lung injury improves cerebral tissue oxygenation. Anesth Analg 2009;109:847-55.
42. Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med 2012;185:1307-15.
43. Fries M, Bickenbach J, Henzler D, Beckers S, Dembinski R, Sellhaus B, et al. S-100 protein and neurohistopathologic changes in a porcine model of acute lung injury. Anesthesiology 2005;102:761-7.
44. Bickenbach J, Biener I, Czaplik M, Nolte K, Dembinski R, Marx
G, et al. Neurological outcome after experimental lung injury. Respir Physiol Neurobiol 2011;179:174-80.

45. Bassi TG, Rohrs EC, Reynolds SC. Systematic review of cognitive impairment and brain insult after mechanical ventilation. Crit Care 2021;25:39.

46. Hopkins RO, Gale SD, Weaver LK. Brain atrophy and cognitive impairment in survivors of acute respiratory distress syndrome. Brain Inj 2006;20:263-71.

47. Kamuf J, Garcia-Bardon A, Ziebart A, Thomas R, Folkert K, Frauenknecht K, et al. Lung injury does not aggravate mechanical ventilation-induced early cerebral inflammation or apoptosis in an animal model. PLoS One 2018;13:e0202131.

48. Al-Attar R, Childers CL, Nguyen VC, Pamerente M, Storey KB. Differential protein phosphorylation is responsible for hypoxia-induced regulation of the Akt/mTOR pathway in naked mole rats. Comp Biochem Physiol A Mol Integr Physiol 2020;242:110653.

49. Caricato A, Conti G, Della Corte F, Mancino A, Santilli F, Sandroni C, et al. Effects of PEEP on the intracranial system of patients with head injury and subarachnoid hemorrhage: the role of respiratory system compliance. J Trauma 2005;58:571-6.

50. Heuer JP, Pelosi P, Hermann P, Perske C, Crozier TA, Brück W, et al. Acute effects of intracranial hypertension and ARDS on pulmonary and neuronal damage: a randomized experimental study in pigs. Intensive Care Med 2011;37:1182-91.

51. Robba C, Poole D, McNett M, Asehnoune K, Bösel J, Bruder N, et al. Mechanical ventilation in patients with acute brain injury: recommendations of the European Society of Intensive Care Medicine consensus. Intensive Care Med 2020;46:2397-410.

52. Della Torre V, Badenes R, Corradi F, Raccia F, Lavinio A, Matta B, et al. Acute respiratory distress syndrome in traumatic brain injury: how do we manage it? J Thorac Dis 2017;9:5368-81.

53. Mascia L, Zavala E, Bosma K, Pasero D, Decaroli D, Andrews P, et al. High tidal volume is associated with the development of acute lung injury after severe brain injury: an international observational study. Crit Care Med 2007;3:5:181:15-20.

54. Krebs J, Tsagogiorgas C, Pelosi P, Rocchi PR, Hottenrott M, Sticht C, et al. Open lung approach with low tidal volume mechanical ventilation attenuates lung injury in rats with massive brain damage. Crit Care 2014;18:R59.

55. Borsellino B, Schultz MJ, Gama de Abreu M, Robba C, Bilotta F. Mechanical ventilation in neurocritical care patients: a systematic literature review. Expert Rev Respir Med 2016;10:1123-32.

56. Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017;80:6-15.

57. Asehnoune K, Roquilly A, Cinotti R. Respiratory management in patients with severe brain injury. Crit Care 2018;22:76.

58. Chapin JC, Downs JB, Douglas ME, Murphy EJ, Ruiz BC. Lung expansion, airway pressure transmission, and positive end-expiratory pressure. Arch Surg 1979;114:193-7.

59. Nemer SN, Caldeira JB, Santos RG, Guimarães BL, Garcia JM, Prado D, et al. Effects of positive end-expiratory pressure on brain tissue oxygen pressure of severe traumatic brain injury patients with acute respiratory distress syndrome: a pilot study. J Crit Care 2015;30:1263-6.

60. Chen H, Chen K, Xu IJ, Zhang YR, Yu RG, Zhou JX. Intracranial pressure responsiveness to positive end-expiratory pressure is influenced by chest wall elastance: a physiological study in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol 2018;18:124.

61. Ashton-Cleary DT, Duffy MR. Prone ventilation for refractory hypoxaemia in a patient with severe chest wall disruption and traumatic brain injury. Br J Anaesth 2011;107:1009-10.

62. Robba C, Rebora P, Banzato E, Wiegers E, Stocchetti N, Menon DK, et al. Incidence, risk factors, and effects on outcome of ventilator-associated pneumonia in patients with traumatic brain injury: analysis of a large, multicenter, prospective, observational longitudinal study. Chest 2020;158:2292-303.

63. Kerr N, de Rivero Vaccari JP, Dietrich WD, Keane RW. Neuronal-respiratory inflammasome axis in traumatic brain injury. Exp Neurol 2020;323:113080.

64. Bortolotti P, Faure E, Kipnis E. Inflammasomes in tissue damage and immune disorders after trauma. Front Immunol 2018;9:11900.

65. Lee SW, de Rivero Vaccari JP, Truettner JS, Dietrich WD, Keane RW. The role of microglial inflammasome activation in pyroptotic cell death following penetrating traumatic brain injury. J Neuroinflammation 2019;16:27.

66. Kerr NA, de Rivero Vaccari JP, Weaver C, Dietrich WD, Ahmed T, Keane RW. Enoxaparin attenuates acute lung injury and inflammasome activation after traumatic brain injury. J Neurotrauma 2021;38:646-54.